Results from the phase II Shorespan-004 trial, to be presented at #ASH25, indicate that oral #bomedemstat effectively reduced hematocrit to less than 45% by week 36 in 45% of patients with previously treated #PolycythemiaVera: https://ow.ly/2bmS50XCMyM
#HemeSky #MedSky

Merck、ASH 2025で血液がん新薬MK-1045・bomedemstat・nemtabrutinibなど20超の新データを発表 | STELLANEWS.LIFE MerckはASH 2025にて、CD19xCD3 T細胞エンゲージャーMK-1045、LSD1阻害剤bomedemstat、BTK阻害剤nemtabrutinibなど、血液がん領域における複数のモダリティの新データを発表予定。20本以上のアブストラクトで技術進展を示す。

Merck to Present Over 20 New Hematology Data Sets at ASH 2025, Highlighting Next-Generation Oncology Pipeline

🔗 Full article: stellanews.life/technology_c...

#Merck #MSD #ASH2025 #Hematology #Oncology #ClinicalResearch #BTKinhibitor #ADC #TCellEngager #Bomedemstat #Nemtabrutinib #Biopharma